Bioxyne Signs Manufacture, Supply Deal with Cannabis Company; Shares Down 3%

MT Newswires Live

Nov 03, 2025

Bioxyne (ASX:BXN), through its Breathe Life Sciences subsidiary, signed an exclusive import, manufacture, and supply agreement with Curaleaf International for the Australian market, according to a Monday filing with the Australian bourse.

Breathe Life Sciences will launch Curaleaf's Que Medical Inhalation Device (QMID) in Australia this month, upon receiving import approval notification from the Therapeutic Goods Administration and authorization from the Office of Drug Control, the filing said.

QMID is the first EU Class IIa medical device for use with medical cannabis liquid inhalants.

The deal is expected to support the company's fiscal year 2026 revenue guidance of AU$65 million to AU$75 million and earnings before interest, taxes, depreciation, and amortization guidance of AU$11.5 million to AU$13.5 million, per the filing.

Bioxyne shares fell nearly 3% in afternoon trade on Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580251411"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580251411\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580251411?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 11:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580251411","market":"sg","top_or_hot":-1,"title":"Bioxyne Signs Manufacture, Supply Deal with Cannabis Company; Shares Down 3%","media":"MT Newswires Live","content":"<html><body><p> Bioxyne (ASX:BXN), through its Breathe Life Sciences subsidiary, signed an exclusive import, manufacture, and supply agreement with Curaleaf International for the Australian market, according to a Monday filing with the Australian bourse.</p><p>Breathe Life Sciences will launch Curaleaf's Que Medical Inhalation Device (QMID) in Australia this month, upon receiving import approval notification from the Therapeutic Goods Administration and authorization from the Office of Drug Control, the filing said.</p><p>QMID is the first EU Class IIa medical device for use with medical cannabis liquid inhalants.</p><p>The deal is expected to support the company's fiscal year 2026 revenue guidance of AU$65 million to AU$75 million and earnings before interest, taxes, depreciation, and amortization guidance of AU$11.5 million to AU$13.5 million, per the filing.</p><p>Bioxyne shares fell nearly 3% in afternoon trade on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bioxyne Signs Manufacture, Supply Deal with Cannabis Company; Shares Down 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioxyne Signs Manufacture, Supply Deal with Cannabis Company; Shares Down 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-03 11:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Bioxyne (ASX:BXN), through its Breathe Life Sciences subsidiary, signed an exclusive import, manufacture, and supply agreement with Curaleaf International for the Australian market, according to a Monday filing with the Australian bourse.</p><p>Breathe Life Sciences will launch Curaleaf's Que Medical Inhalation Device (QMID) in Australia this month, upon receiving import approval notification from the Therapeutic Goods Administration and authorization from the Office of Drug Control, the filing said.</p><p>QMID is the first EU Class IIa medical device for use with medical cannabis liquid inhalants.</p><p>The deal is expected to support the company's fiscal year 2026 revenue guidance of AU$65 million to AU$75 million and earnings before interest, taxes, depreciation, and amortization guidance of AU$11.5 million to AU$13.5 million, per the filing.</p><p>Bioxyne shares fell nearly 3% in afternoon trade on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7111","symbol_name":"个人用品","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2580251411","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580251411","pubTimestamp":1762139753,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Bioxyne , through its Breathe Life Sciences subsidiary, signed an exclusive import, manufacture, and supply agreement with Curaleaf International for the Australian market, according to a Monday filing with the Australian bourse.Breathe Life Sciences will launch Curaleaf's Que Medical Inhalation Device  in Australia this month, upon receiving import approval notification from the Therapeutic Goods Administration and authorization from the Office of Drug Control, the filing said.QMID is the first EU Class IIa medical device for use with medical cannabis liquid inhalants.The deal is expected to support the company's fiscal year 2026 revenue guidance of AU$65 million to AU$75 million and earnings before interest, taxes, depreciation, and amortization guidance of AU$11.5 million to AU$13.5 million, per the filing.Bioxyne shares fell nearly 3% in afternoon trade on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7111":"个人用品","XKO.AU":"标普/澳交所 300指数","XAO.AU":"标普/澳交所 普通股指数","QMID":"WISDOMTREE U.S. MIDCAP QUALITY GROWTH FUND","BXN.AU":"BIOXYNE LTD","XJO.AU":"标普/澳交所 200指数","BK7508":"医药生物股"},"translate_title":"Bioxyne与大麻公司签署制造、供应协议；股价下跌3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XKO.AU":0.9,"QMID":1,"XJO.AU":0.9,"BXN.AU":1,"XAO.AU":0.9},"content_text":"Bioxyne (ASX:BXN), through its Breathe Life Sciences subsidiary, signed an exclusive import, manufacture, and supply agreement with Curaleaf International for the Australian market, according to a Monday filing with the Australian bourse.Breathe Life Sciences will launch Curaleaf's Que Medical Inhalation Device (QMID) in Australia this month, upon receiving import approval notification from the Therapeutic Goods Administration and authorization from the Office of Drug Control, the filing said.QMID is the first EU Class IIa medical device for use with medical cannabis liquid inhalants.The deal is expected to support the company's fiscal year 2026 revenue guidance of AU$65 million to AU$75 million and earnings before interest, taxes, depreciation, and amortization guidance of AU$11.5 million to AU$13.5 million, per the filing.Bioxyne shares fell nearly 3% in afternoon trade on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}